Clinical trials: Cerebral Disorder
Parkinson Disease
Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor
Demonstrate safety and efficacy of TAPS delivered by a Cala device as a treatment for action tremor in subjects with Parkinson's disease hand tremor
- Trial name
- NCT05012579
- Testing
- Cala Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cala Health, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Addressing Dementia Via Agitation-Centered Evaluation
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Trial name
- ADVANCE (NCT03226522)
- Testing
- AXS-05, Bupropion
- Where
- 78 sites in United States, Australia
- Volunteers
- 366 people
- Sponsor
- Axsome Therapeutics, Inc.
Inherited Metabolic Disorders (IMD)
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
- Trial name
- NCT03406962
- Testing
- MGTA-456
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Magenta Therapeutics, Inc.
Arterial Ischemic Stroke
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain…
- Trial name
- NCT04962503
- Testing
- Afamelanotide
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Parkinson's Disease
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's…
- Trial name
- NCT00642356
- Testing
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis
Epilepsy
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to…
- Trial name
- OPTIMAL (NCT01498822)
- Testing
- Levetiracetam, Oxcarbazepine
- Where
- 23 sites in South Korea
- Volunteers
- 353 people
- Sponsor
- Korea UCB Co., Ltd.
Acromegaly
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to…
- Trial name
- OPTIMAL (NCT03252353)
- Testing
- octreotide capsules
- Where
- 60 sites in United States, Australia and 15 more
- Volunteers
- 56 people
- Sponsor
- Chiasma, Inc.
Dwarfism, Growth Hormone Deficiency
Drug Use Investigation of Somatropin for GHD-ADULTS.
Post marketing drug use investigation of Genotropin for GHD-ADULTS.
- Trial name
- NCT00601419
- Testing
- Somatropin
- Volunteers
- 230 people
- Sponsor
- Pfizer
Dementia With Lewy Bodies, REM Sleep Behavior Disorder
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia…
- Conditions
- Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
- Trial name
- NCT02708186
- Testing
- Nelotanserin
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Axovant Sciences Ltd.
Japanese Encephalitis
Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The study investigates the long term persistence the Japanese encephalitis vaccine IC51 and the need of a booster dose
- Trial name
- NCT00595270
- Testing
- IC51
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
- Trial name
- RELIEF (NCT04152083)
- Testing
- Eptinezumab
- Where
- 57 sites in United States, Georgia
- Volunteers
- 485 people
- Sponsor
- H. Lundbeck A/S
Fabry Disease, Lysosomal Storage Diseases
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
Fabry disease is a rare, X-linked inborn error of glycosphingolipid metabolism caused by an abnormal gene encoding the α-galactosidase A (αGLA) enzyme.
- Trial name
- NCT04455230
- Testing
- FLT190
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Spur Therapeutics
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
Carotid Stenosis
CorMatrix ECM for Carotid Repair Following Endarterectomy Registry
Assess device performance data from subjects undergoing patch angioplasty of the carotid artery following carotid endarterectomy using the CorMatrix ECM for Carotid Repair.
- Trial name
- NCT01569594
- Testing
- CorMatrix ECM for Carotid Repair
- Where
- 6 sites in United States
- Volunteers
- 230 people
- Sponsor
- Elutia Inc.
Alzheimer Disease, Dementia
SAFE at Home: A Service to Provide Social Engagement to Community-Dwelling Persons With Dementia
The proposed Phase 1 study will involve initial development and evaluation of a new service called Social Activities For Engagement at Home or SAFE at Home (SaH).
- Conditions
- Alzheimer Disease, Dementia, Dementia, Vascular, Dementia, Mixed
- Trial name
- NCT05516147
- Testing
- SAFE at Home
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hopeful Aging
Japanese Encephalitis
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the…
- Trial name
- NCT00776230
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Gaucher Disease
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
The primary objective of this study was to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had demonstrated…
- Trial name
- NCT01074944
- Testing
- Eliglustat tartrate
- Where
- 46 sites in United States, Australia and 15 more
- Volunteers
- 170 people
- Sponsor
- Genzyme, a Sanofi Company
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
CDKL5 Deficiency Disorder
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.
- Trial name
- Marigold (NCT03572933)
- Testing
- ganaxolone
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 101 people
- Sponsor
- Marinus Pharmaceuticals
Stroke
Rehabilitation of the Stroke Hand at Home
The purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care.
- Trial name
- HAAPI (NCT01144715)
- Testing
- Hand Mentor (TM) robotic stroke therapy device, Home Therapy Program
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Kinetic Muscles